Pharmascience
- Company typePrivate
- Founded1984
- HeadquartersMontréal, Canada
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Pharmascience firmographics
Firmographics- Name
- Pharmascience
- Legal name
- Pharmascience Inc.
- Website
- https://pharmascience.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Pharmascience industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Generic Hospital & Institutional Products (HLAIABAL), Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Pharmascience is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Pharmascience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Generic Pharmaceutical Sales: Pharmascience generates revenue through development and sale of generic pharmaceutical products. Revenue is realized through product launches following regulatory approvals, with income from manufacturing and distributing generic equivalents of branded medications.
Go-to-market motion3 records
Distribution channels2 records
Pharmascience product offering
Product offeringCore offering
Pharmascience develops, manufactures, and commercializes generic and specialty pharmaceutical products, with a focus on FDA ANDA-approved bioequivalent formulations and Canadian distribution of specialty/orphan drugs. Its portfolio includes generic oncology products such as Dasatinib Tablets and rare-disease therapies such as YORVIPATH (TransCon PTH) distributed via its Pendopharm division. The company invests approximately $50–55 million annually in R&D and partners with global pharmaceutical firms for international commercialization.
Product overview
Pharmascience is a Canadian pharmaceutical company headquartered in Montreal that develops and commercializes generic pharmaceutical products. The company's portfolio includes generic oncology medications such as Dasatinib Tablets (developed in partnership with Lupin for treating leukemia) and specialty products like YORVIPATH® (TransCon™ PTH) for chronic hypoparathyroidism, distributed through its Pendopharm division. The company maintains consistent R&D investment of approximately $50–$55 million annually and has been ranked among Canada's Top 100 Corporate R&D Spenders for 20 consecutive years.
Differentiator
Problem solved
Functional benefit
Brands
- Pendopharm: A division of Pharmascience Inc. specializing in distribution of specialty pharmaceutical products in Canada
Products and services
- Dasatinib Tablets Generic oncology medication for treating Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in adults and pediatric patients. Bioequivalent to Bristol-Myers Squibb's Sprycel Tablets and available in multiple dosage strengths (20 mg to 140 mg). The U.S. market value was estimated at USD 930 million as of October 2025.
- YORVIPATH (TransCon PTH) Specialty treatment for chronic hypoparathyroidism. The first approved treatment option available to patients in Canada for this rare condition. Distributed exclusively through Pendopharm, a division of Pharmascience Inc. Holds orphan drug designation in the European Union.
Quantifiable outcome
- Generic Dasatinib achieved estimated annual US market value of USD 930 million (October 2025)
Companies that use Pharmascience
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Pharmascience technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pharmascience partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- LupincorePharmascience partnered with Lupin to develop Dasatinib Tablets, a generic bioequivalent to Bristol-Myers Squibb's Sprycel. The partnership received FDA approval for ANDA and the product was launched in the US market in multiple dosage strengths (20mg to 140mg). The generic equivalent had an estimated annual market value of USD 930 million in the US as of October 2025.
- Ascendis PharmacoreExclusive distribution agreement where Pendopharm, a division of Pharmascience Inc., distributes YORVIPATH (TransCon PTH) in Canada. This is the first approved treatment for chronic hypoparathyroidism available to Canadian patients. YORVIPATH holds orphan drug designation in the European Union.
- Pendopharm (Division of Pharmascience)coreInternal division of Pharmascience responsible for distribution operations within the Canadian pharmaceutical market. Handles distribution of specialty and rare disease medications including YORVIPATH.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Pharmascience competitors and assessment
Company assessmentDirect peers
- Endo International: Specialty and generic pharmaceutical company with strong US franchise in sterile injectables, generics, and specialty therapeutics. Comparable in the specialty-generic hybrid model and US distribution capabilities.
- Apotex Inc. Canadian-headquartered generic pharmaceutical manufacturer with comparable small-molecule generic development, ANDA filings, and a large Canadian distribution footprint. Direct competitor in the Canadian generics market and a peer in R&D scale.
- Sun Pharmaceutical Industries: Indian-headquartered global generic manufacturer with strong ANDA pipeline, specialty pharmaceutical division, and US market presence. Comparable in scale, business model, and therapeutic area overlap with Pharmascience.
- Lupin Pharmaceuticals: Indian-headquartered global generic manufacturer and Pharmascience's US commercialization partner for Dasatinib. Directly comparable in ANDA capabilities, small-molecule generics, and US market focus — also a likely direct competitor in many generic molecules.
- Aurobindo Pharma: Indian generic pharmaceutical manufacturer with extensive ANDA filings and a significant US generic footprint. Comparable in formulation development capabilities and competitive positioning in US generic oncology and chronic disease markets.
Broad incumbents
- Sandoz (Novartis): Global generic and biosimilar pharmaceutical company spun out of Novartis. Directly comparable as a large-scale generic manufacturer with ANDA capabilities, global commercial reach, and a similar product portfolio overlap with Pharmascience.
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with deep ANDA expertise and global distribution. Competes head-to-head with Pharmascience in the US generic oncology market (Dasatinib) and shares the same ANDA-based business model.
- Viatris (formerly Mylan): Global healthcare company formed from Mylan and Upjohn, with a major generic and specialty pharmaceutical franchise. Competes with Pharmascience across multiple therapeutic areas and shares ANDA-driven business model.
Emerging players
- Ascendis Pharma: Danish specialty pharmaceutical company that partnered with Pharmascience's Pendopharm division to commercialize YORVIPATH in Canada. Comparable as a partner with overlapping interests in rare disease and specialty endocrinology therapeutics.
Regional players
- Bausch Health Companies: Canadian-headquartered specialty pharmaceutical company with both branded and generic/specialty operations. Comparable as a Canadian pharma peer with overlapping specialty distribution and pharmaceutical product portfolios.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Pharmascience social profiles
Digital presencePharmascience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharmascience leadership team
Management profileNumber of profiles
Profiles3 records
Pharmascience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Pharmascience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharmascience M&A and investment
M&A and investmentM&A1 record
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharmascience
What does Pharmascience do?
Pharmascience develops, manufactures, and commercializes generic and specialty pharmaceutical products, with a focus on FDA ANDA-approved bioequivalent formulations and Canadian distribution of specialty/orphan drugs. Its portfolio includes generic oncology products such as Dasatinib Tablets and rare-disease therapies such as YORVIPATH (TransCon PTH) distributed via its Pendopharm division. The company invests approximately $50–55 million annually in R&D and partners with global pharmaceutical firms for international commercialization.
Is Pharmascience a public or private company?
Pharmascience is a private company. It is classified as family owned and is currently operating.
When was Pharmascience founded?
Pharmascience was founded in 1984. It employs 1,001 to 5,000 people.
Where is Pharmascience based?
Pharmascience is headquartered in Montréal, Canada, in the North America region.
How does Pharmascience make money?
One revenue line is on record: generic Pharmaceutical Sales.
Who are Pharmascience's main competitors?
Direct peers on record are Endo International, Apotex Inc., Sun Pharmaceutical Industries, Lupin Pharmaceuticals and Aurobindo Pharma. Broad incumbents are Sandoz (Novartis), Teva Pharmaceutical Industries and Viatris (formerly Mylan). Ascendis Pharma is listed as an emerging player. Bausch Health Companies is listed as a regional player.
Does Pharmascience have an API?
No public API is recorded for Pharmascience.
What industry is Pharmascience in?
Pharmascience's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.